Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06562608 · ClinicalTrials.gov registry record · Phase 4
Anticholinergic Deprescription in Schizophrenia
A Phase 4 study of Schizophrenia and Schizoaffective Disorder, sponsored by Deepak K. Sarpal, M.D..
- Recruiting
- Registry status
- Phase 4
- Development phase
- 105
- Enrollment target
- 1
- Study location
NCT06562608: Recruiting Phase 4 study of Schizophrenia and Schizoaffective Disorder, sponsored by Deepak K. Sarpal, M.D..
NCT06562608 is a Phase 4 study of Schizophrenia and Schizoaffective Disorder that is actively recruiting participants, run by Deepak K. Sarpal, M.D.. The registered enrollment target is 105 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06562608, a Phase 4 study of Schizophrenia and Schizoaffective Disorder, is actively recruiting participants, sponsored by Deepak K. Sarpal, M.D..
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 105 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, the investigators will examine whether a deprescription of unnecessary anticholinergic drugs (benztropine or trihexyphenidyl) can augment quality of life, functioning, and neurocognition in individuals who with schizophrenia. Individuals identified by clinical services who have unneeded prescriptions benztropine or trihexyphenidyl will be eligible for deprescription and study entry. Following a baseline evaluation and magnetic resonance imaging (MRI), participants will will be randomized to either staying on their anticholinergic drugs or undergoing deprescription per routine clinical care, and will undergo follow-up evaluations across 6 months. The investigators predict that reducing and deprescribing these drug, if clinically determined to be unnecessary will will enhance functioning, neurocognition
Primary Outcome
We will examine whether the anticholinergic deprescription group, relative to the non-deprescription group, shows an increase in cognitive performance via scores from the MATRICS Consensus Cognitive Battery.
Conditions Studied
Interventions
- DRUG Anticholinergic Deprescription
- DRUG No Anticholinergic Deprescription
Study Locations (1)
Pennsylvania
- UPMC Western Psychiatric Hospital/University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 4 |
What NCT06562608 shows while recruiting
NCT06562608 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (52% lower).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Anticholinergic Deprescription is the first listed.
NCT06562608 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06562608 about?
NCT06562608 is a clinical study titled "Anticholinergic Deprescription in Schizophrenia". In this study, the investigators will examine whether a deprescription of unnecessary anticholinergic drugs (benztropine or trihexyphenidyl) can augment quality of life, functioning, and neurocognition in individuals who with schizophrenia. Individuals identified by clinical services who have unneed...
What is the current status of trial NCT06562608?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 105 participants. The study started on 2025-02-01. Estimated completion is 2029-06-30.
What conditions does trial NCT06562608 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT06562608?
The interventions under investigation include: Anticholinergic Deprescription (DRUG), No Anticholinergic Deprescription (DRUG).
Who is sponsoring clinical trial NCT06562608?
This trial is sponsored by Deepak K. Sarpal, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06562608 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06562608's enrollment target sits among peer trials
105 134th of 315 higher than 181 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI